{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:04:11Z","timestamp":1781273051492,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","award":["YQ202302"],"award-info":[{"award-number":["YQ202302"]}],"id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118804","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:07:48Z","timestamp":1774714068000},"page":"118804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity"],"prefix":"10.1016","volume":"311","author":[{"given":"Xiaoyu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-3424","authenticated-orcid":false,"given":"Anhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118804_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216831","article-title":"Colorectal cancer initiation: understanding early-stage disease for intervention","volume":"589","author":"Jiang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118804_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14712598.2019.1595580","article-title":"FOLFOXIRI plus biologics in advanced colorectal cancer","volume":"19","author":"Garc\u00eda-Alfonso","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.118804_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438466","article-title":"State-of-the-Art management of colorectal cancer: treatment advances and innovation","volume":"44","author":"Pathak","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejmech.2026.118804_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/PAI.0000000000001089","article-title":"Intraindividual tumor heterogeneity of mismatch repair status in metastatic colorectal cancer","volume":"31","author":"Huang","year":"2023","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ejmech.2026.118804_bib5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/ijms23052519","article-title":"Drug-resistant stem cells: novel approach for Colon cancer therapy","volume":"23","author":"Telang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118804_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.critrevonc.2010.01.010","article-title":"Colon cancer","volume":"74","author":"Labianca","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.118804_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.10.009","article-title":"Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"106","author":"Baraniskin","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118804_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14712598.2020.1718095","article-title":"Pembrolizumab for the treatment of colorectal cancer","volume":"20","author":"Coupez","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.118804_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canlet.2017.03.023","article-title":"Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer","volume":"396","author":"Koustas","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118804_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116807","article-title":"Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma","volume":"279","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118804_bib12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.279.5356.1534","article-title":"A model for the mechanism of human topoisomerase I","volume":"279","author":"Stewart","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118804_bib13","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-024-49567-5","article-title":"Topoisomerase I is an evolutionarily conserved key regulator for satellite DNA transcription","volume":"15","author":"Teng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118804_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118804_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","article-title":"A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade","volume":"171","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib16","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118804_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106652","article-title":"Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I","volume":"139","author":"Zhang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-19-1064","article-title":"The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2","volume":"19","author":"Marzi","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118804_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1749-6632.2000.tb07028.x","article-title":"Preclinical and clinical trials of topoisomerase inhibitors","volume":"922","author":"Saijo","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.118804_bib20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1535-7163.MCT-10-1043","article-title":"Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282","volume":"10","author":"Sooryakumar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118804_bib21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.bmcl.2017.03.039","article-title":"Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors","volume":"27","author":"Dong","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2026.118804_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116595","article-title":"Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents","volume":"55","author":"Hao","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117611","article-title":"Topoisomerase II-targeting anticancer clinical candidates and drugs: a critical analysis, unravelling molecular medicinal insights and promising research roadmap","volume":"291","author":"Acharya","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib24","article-title":"Progress of anti-tumor research on natural products combined with doxorubicin","volume":"189","author":"Wu","year":"2025","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2026.118804_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bmc.2010.10.057","article-title":"3-Arylisoquinolines as novel topoisomerase I inhibitors","volume":"19","author":"Khadka","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118804_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/bab.1346","article-title":"DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation","volume":"63","author":"Singh","year":"2016","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ejmech.2026.118804_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1389203718666170111114442","article-title":"Natural product inhibitors of topoisomerases: review and docking study","volume":"19","author":"Scotti","year":"2018","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ejmech.2026.118804_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2023.105525","article-title":"Integrated analysis of topoisomerase I inhibitors from flavonoids of Scutellaria baicalensis Georgi using bioaffinity ultrafiltration UPLC-TripleTOF MS\/MS, molecular docking and target-based multiple complex networks","volume":"168","author":"Tan","year":"2023","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2026.118804_bib29","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.3390\/molecules29153547","article-title":"Inhibition of DNA topoisomerase \u0399 by flavonoids and polyacetylenes isolated from Bidens pilosa L","volume":"29","author":"Zeng","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118804_bib30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12672-025-01996-4","article-title":"Probiotics in colorectal cancer prevention and therapy: mechanisms, benefits, and challenges","volume":"16","author":"Morsli","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ejmech.2026.118804_bib31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10585-022-10163-w","article-title":"The role of epigenetic modifications in colorectal cancer metastasis","volume":"39","author":"Su","year":"2022","journal-title":"Clin. Exp. Metastasis"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:45:49Z","timestamp":1781271949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0223523426002497"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118804","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118804"}}